Tumour cells that are HER2+ have an advanced extravasative potential that results in an aggressive form of the disease that is often resistant to many cytotoxic drugs and is associated with significantly decreased disease-free survival (DFS) and OS [138, 197, 257]. The gene discussed is ERBB2; the disease is neoplasm.